Gesynta Pharma is a privately-held pharmaceutical company developing novel oral treatments for patients with chronic inflammatory conditions
Location: Sweden
Total raised: $48.13M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Industrifo... | industrifo... |
| - | Hadean Ven... | hadeanvent... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.01.2025 | - | $27.62M | - |
| 07.07.2020 | - | $20.52M | Industrifo... |
Mentions in press and media 11
| Date | Title | Description |
| 17.03.2026 | /C O R R E C T I O N -- Gesynta Pharma/ | In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as ... |
| 11.03.2026 | First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat | STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for end... |
| 11.03.2026 | First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat | First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat Wed, Mar 11, 2026 14:00 CET Report this content STOCKHOLM, SWEDEN – March 11, 2026. Gesynta Pharma AB today announced that the first patient has been dosed in its P... |
| 22.12.2025 | Gesynta Pharma forms Scientific Advisory Board with international endometriosis experts | Gesynta Pharma forms Scientific Advisory Board with international endometriosis experts Mon, Dec 22, 2025 08:15 CET Report this content STOCKHOLM, SWEDEN - December 22nd, 2025. Gesynta Pharma AB today announced the formation of a Scientific... |
| 30.09.2025 | Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis | Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis Tue, Sep 30, 2025 08:00 CET Report this content STOCKHOLM, SWEDEN - September 30, 2025. Gesynta Pharma AB today announced that its clinical trial appli... |
| 22.07.2025 | Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m - HealthCap and Hadean Growth Fund Join Strong Investor Syndicate | Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m - HealthCap and Hadean Growth Fund Join Strong Investor Syndicate Tue, Jul 22, 2025 10:00 CET Report this content STOCKHOLM, SWEDEN - July 22, 2025. Gesynta Pharma AB... |
| 09.04.2025 | Gesynta Pharma AB Appoints Eva Johnsson as new Chief Medical Officer (CMO) / VP Clinical Development | Gesynta Pharma AB Appoints Eva Johnsson as new Chief Medical Officer (CMO) / VP Clinical Development Wed, Apr 09, 2025 14:00 CET Report this content Stockholm, Sweden - April 9, 2025. Gesynta Pharma AB, a clinical-stage pharmaceutical compa... |
| 20.01.2025 | Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment | Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment Mon, Jan 20, 2025 08:45 CET Report this content STOCKHOLM, SWEDEN - January 20, 2025. Gesynta Pharma AB announces that it has secured SEK 304 million in a Series... |
| 15.06.2021 | Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248 | Stockholm, Sweden, June 14 2021 Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248IND submitted for systemic sclerosis and 50% recruitment milestone in Phase II study reached. ... |
| 26.01.2021 | Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients with systemic sclerosis | Stockholm, Sweden, January 26, 2020 – Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis – a debilitating autoimmune disease... |
Show more